Mayor Rahm Emanuel Proclaims November 8th as Chicago Alzheimer's Awareness Day

Great Lakes Clinical Trials is proud to announce that Chicago Mayor Rahm Emanuel has officially proclaimed November 8th as “Chicago Alzheimer's Awareness Day”. This proclamation is associated with a citywide event taking place at the Swedish American Museum on November 8th to help raise awareness about the disease and to honor those volunteers that have taken steps to participate in research studies to help find a treatment, cure or prevention.

“I am so proud to be a lifelong resident and business owner in the City of Chicago, which recognizes the tireless achievements of medical research clinics and more importantly, the local residents who volunteer take part in clinical trials,” commented Steve Satek, President of Great Lakes Clinical Trials. “Without the participation of our senior community in research studies, we will never find a treatment or cure for Alzheimer’s disease. We are grateful for those that volunteer their time to join trials at Great Lakes Clinical Trials, as well as our many other research centers across Chicagoland”.

More information on the November 8th “Chicago Alzheimer's Awareness Day” event can be found on the Great Lakes Clinical Trials “Events” page or by clicking here.

The following is text from Mayor Emanuel’s proclamation. In addition, you can download an official copy of the proclamation by clicking here

GLCT AlzDay18 Proclamation.jpg


WHEREAS, the City of Chicago is home to approximately 2.7 million residents, with over 300,000 over the age of 65, and takes pride in promoting a healthy lifestyle with a continued strong quality of life as the population ages; and

WHEREAS, Chicago is home to world-class medical research organizations that focus on developing treatments and a possible cure for memory loss and Alzheimer's disease; and

WHEREAS, Great Lakes Clinical Trials is an internationally-recognized medical research clinic located on the north side of Chicago that is committed to providing free access to global research trials in the areas of memory loss and Alzheimer's disease to the community; and

WHEREAS, the Memory Care Coalition of Chicago is a non-profit community comprised of organizations, support groups, and healthcare providers, all of whom are dedicated to improving the quality of life for seniors and their caregivers in an effort to ensure that seniors receive the quality healthcare and support needed to face the challenges of memory loss; and

WHEREAS, the City of Chicago joins Great Lakes Clinical Trials and the Memory Care Coalition of Chicago in supporting the vision of the Alzheimer's Association, "A World Without Alzheimer's Disease"; and

WHEREAS, there are currently no treatments to prevent, or slow down the progression of Alzheimer's disease, and of over I 0,000 adults, 62% are worried that they may develop Alzheimer's disease and 91 % believe the solution to eradicating this disease lies in medical research, showing the importance and necessity of clinical research trails to develop such advances; and

WHEREAS, Great Lakes Clinical Trials and the Memory Care Coalition of Chicago are dedicated to raising awareness of Alzheimer's disease research and the importance of participation in clinical trials to find a cure, through community education:

NOW, THEREFORE, I, RAHM EMANUEL, MAYOR OF THE CITY OF CHICAGO, do hereby proclaim November 8, 2018 to be CHICAGO ALZHEIMER'S AWARENESS DAY in recognition of the tireless work and ongoing contributions of the research community in finding a cure for Alzheimer's disease. Dated this 25th day of September, 2018. 

#GLCT #ChicagoAlzDay2018

Digestive Health - Let’s talk about Constipation!

It’s ok to talk about constipation because we all have bowel movements!


Constipation happens when we experience hard to pass or infrequent bowel movements, hard or lumpy stools, or when our bowel movements leave us with the feeling of being incomplete. Irregular or difficult bowel habits can be uncomfortable, disruptive to our daily routines, and decrease our feeling of wellbeing. Added together constipation can affect our mood, decrease our comfort and restrict our quality of life.  In recent years there has been lots of media coverage and corporate advertising giving attention to gut-health including the use of pre- and pro-biotics.

The first step towards improving digestive health is understanding what is normal for you and that not everyone needs to have a bowel movement each day. Perceptions of constipation often vary based upon our own personal experience, family, and culture. While approximately 38% of the population reports symptoms of constipation it is normal for all of us to experience some of these symptoms from time to time depending on the foods we are eating.

In most cases constipation is a symptom, not a disease. Not eating enough fruits, vegetables, and whole grains can contribute to the symptoms of constipation. Often constipation can be managed through changes to your diet, drinking more fluids, and exercise. There are even some new and exciting natural health products that offer solutions to improve bowl health and regularity. 

At Great Lakes Clinical Trials, we study digestive function by researching various probiotics and prebiotics to understand the mechanisms by which they can improve gut bacteria while gently offering laxative effects. As an example kiwi fiber acts as a prebiotic promoting good gut bacteria. Additionally, research has shown kiwi fibers have the capacity to swell up to 12x greater than traditional wheat bran adding much needed bulk to stool. Actinidin, an enzyme found exclusively in green kiwifruit, acts to enhance the digestion of food proteins.

These supplements have the potential to offer naturally sourced alternatives to many traditional over the counter laxative treatments. Ideally laxatives should only be used occasionally as needed for short periods. Frequent and long-term use can have unforgiving repercussions on digestive health including resulting in laxative dependency. This may decrease the ability of the gut to function normally making the symptoms of constipation worse. Some types of laxatives can adversely interact with the medicines we require and/or disrupt normal electrolyte balance affecting several bodily functions including in the colon, heart, and nervous system.

If you’re interested in learning more about our digestion studies click the button below:

Great Lakes Clinical Trials to Initiate a Study for Hidradenitis Suppurativa (HS)

In October, Great Lakes Clinical Trials will begin enrolling participants for a clinical trial in Hidradenitis Suppurativa (HS), a dermatological condition found in 1-4% of all Americans.

The following information on HS is provided via the Mayo Clinic (

 Hidradenitis suppurativa usually appears as one or more red, tender bumps that fill with pus. It most commonly occurs in the armpits (shown), groin, between the buttocks and under the breasts

Hidradenitis suppurativa usually appears as one or more red, tender bumps that fill with pus. It most commonly occurs in the armpits (shown), groin, between the buttocks and under the breasts

What is HS?

Hidradenitis suppurativa (HS) is a long-term skin condition that features small, painful lumps under the skin. They typically develop where the skin rubs together, such as the armpits, the groin, between the buttocks and under the breasts. The lumps may break open and smell or cause tunnels under the skin.

HS tends to start after puberty. It can persist for many years and worsen over time, with serious effects on your daily life and emotional well-being. Early diagnosis and treatment can help manage the symptoms, keep new lumps from forming and prevent complications, such as scarring or depression.


HS commonly occurs around hair follicles with many oil and sweat glands, such as in the armpits, groin and anal area. It may also occur where skin rubs together, such as the inner thighs, under the breasts and between the buttocks. Hidradenitis suppurativa can affect one spot or multiple areas of the body.

Signs and symptoms of hidradenitis suppurativa include:

  • Blackheads. Small pitted areas of skin containing blackheads — often appearing in pairs or a "double-barreled" pattern — are a common feature.

  • Red, tender bumps. These bumps often enlarge, break open and drain pus. The drainage may have an odor. Itching and burning may accompany the bumps. They usually appear in areas where skin rubs against skin.

  • Painful, pea-sized lumps. These hard lumps, which develop under the skin, may persist for years, enlarge and become inflamed.

  • Tunnels. Over time, tracts connecting the lumps may form under the skin. These wounds heal very slowly, if at all, and can leak pus.

Hidradenitis suppurativa usually starts between puberty and age 40 with a single, painful bump that persists for weeks or months. For some people, the disease progressively worsens and affects multiple areas of their body. Other people experience only mild symptoms. Excess weight, stress, hormonal changes, heat or humidity can worsen symptoms. In women, the disease severity may lessen after menopause.


Hidradenitis suppurativa develops when hair follicles become blocked and inflamed. No one knows exactly why this blockage occurs. Factors that may play a role include hormones, metabolic syndrome, genetics, an irregular immune system response, smoking and excess weight.

Hidradenitis suppurativa is not caused by an infection and can't be transmitted sexually. It's not contagious and is not due to poor hygiene.


If you are interested in learning more about the HS Research Programs at Great Lakes Clinical Trials, you can provide your contact information by clicking the button below, and our team will reach out to you when the study is open for enrollment.

Crain’s Chicago Business Names Steve Satek One of Chicago’s Notable LGBTQ Executives

Chicago, IL – Great Lakes Clinical Trials Founder and President, Steve Satek, is one of Crain's Chicago Business’ Chicago's Notable LGBTQ Executives 2018.

Satek is being recognized for, among other things, his leadership at Great Lakes Clinical Trials which has greatly contributed to it being one of Chicago’s leading clinical research centers.  Great Lakes Clinical Trials was established on the principle of making clinical study opportunities more convenient and comfortable for patients.  This means providing easily accessible locations within neighborhood communities, including Andersonville and Arlington Heights, as well as creating a welcoming atmosphere to patients of all backgrounds, ages and sexual orientations.

 Steve Satek, President Great Lakes Clinical Trials 

Steve Satek, President
Great Lakes Clinical Trials 

Alzheimer’s disease and memory loss are key areas of research for Satek and the team at Great Lakes Clinical Trials. “In recent years we have made good progress towards a cure,” commented Mr. Satek. “There are often a lot of uncertainties in research, but one thing we know for sure is that we will never have a new medication to help treat or prevent Alzheimer’s disease without the participation of older adults in our current research trials.”

By 2030, there will be nearly five million adults aged 60 and older in the U.S. who identify as lesbian, gay, or bisexual.  As advanced age is a key risk factor or Alzheimer’s, Satek has created a community-based, LGBTQ-friendly center where volunteers and care partners can comfortably participate in clinical trials.

“At Great Lakes Clinical Trials, we are patient focused.  We do not see color, race, religion or sexual orientation, but rather we see neighbors, friends and our community,” added Satek.  “Diversity is one of the things I cherish most about growing up and living in the Chicago area.  We are all equals, and I could not be prouder to be recognized for the welcoming culture established at Great Lakes Clinical Trials.”

The research center led by Satek recently joined the Global Alzheimer’s Platform (GAP) Foundation’s invitation only national network of the leading clinical trial sites in Alzheimer’s research. On learning of the Crain’s announcement,  GAP’s president, John Dwyer said, “GAP congratulates Crain’s excellent judgement in selecting Steve as one of Chicago’s Notable LGBTQ Executives. Steve is one of the passionate, dedicated leaders in Alzheimer’s research and shares our commitment to providing access to Alzheimer’s clinical trials to anyone interested in finding a cure for this invidious disease--a disease that does not discriminate on the basis of sex, race, religion or sexual orientation.  Alzheimer’s research and Chicago are lucky to have Steve Satek and Great Lakes Clinical Trials in this fight; the recognition of his leadership is very much deserved.”

For more information about the ongoing research at Great Lakes Clinical Trials, visit:

The announcement was made in Crain’s August 27th print edition as well as online at  This section profiles Chicago's notable LGBTQ executives, specifically those who are advancing their industries and/or workplace equality.

About Great Lakes Clinical Trials

Great Lakes Clinical Trials is an independent, community-based research clinic.  With two Chicago area locations in Andersonville and in Arlington Heights, the Great Lakes team have managed more than 525 clinical trials over the past 25 years and are committed to providing quality services for both study volunteers & the research industry. Great Lakes Clinical Trials specializes in the study of investigational medications, food products, devices and supplements for the treatment of chronic diseases, notably in Mental Health, Memory Disorders, Pain Management, Nutrition and Dermatology. For more information, please visit


To learn more or to inquire about interviews, please contact:
Steve Malito, Media Relations
Great Lakes Clinical Trials
Office: (773) 275-3500
Fax: (773) 275-3501

Research Study for Memory Lapses

Is someone in your life starting to experience Memory Loss?

Great Lakes Clinical Trials - Arlington Heights is now seeking participants for a research study of older adults, ages 60-85, who are starting to experience memory loss, more than would be expected of normal aging.


The PERISCOPE-ALZ Study will examine if an investigational drug, may help to slow or stop memory loss.  There is no cost to participate. Participants will receive all study-related care from a research doctor at no cost and may be compensated per study site visit for time and travel expenses.

Who can join the PERISCOPE-ALZ Study? You may be able to take part if you:

  • are 60–85 years of age
  • have had memory loss for 6 months or more that has become gradually worse over time
  • have a family member or close friend who is with you at least 10 hours per week and can attend study appointments with you.

All medical care, tests and medications are provided at no cost and insurance or Medicare is not required.  In addition, you may receive compensation for your participation.

If you are interested in joining this trial, visit or click here.  Otherwise, you can call our center directly at (847) 301-7480 to speak with one of our staff today.

Great Lakes Supports August as Psoriasis Awareness Month

August is Psoriasis Awareness Month!  The National Psoriasis Foundation has taken the lead on promoting activities throughout the month, by sharing resources for treating and managing psoriatic disease to empower patients to take control of their own health. 

Great Lakes Clinical Trials is supporting these activities through our current clinical research programs in Psoriatic Arthritis and Psoriasis. 

  • Our Psoriatic Arthritis research programs are lead by board-certified Rheumatologist, Manish Jain, MD.  Dr. Jain has been in practice for 9 years and is one of 3 doctors on staff at Presence St. Francis Hospital and one of 4 at Swedish Covenant Hospital who specialize in Rheumatology.  He received his medical degree from Rush Medical College and completed his Rheumatology Fellowship at New York University. 
  • Our Psoriasis research programs are lead by board-certified Dermatologist, Ahmad Shatil Amin, MD.  Besides his research focus at Great Lakes Clinical Trials, Dr. Amin serves as Assistant Professor of Dermatology at Northwestern Memorial Hospital.  Dr, Amin earned his medical degree from University of North Carolina in 2008 and completed his Dermatology Residency University of North Carolina Hospitals in 2012.

If you are interested in joining the Great Lakes Clinical Trials research programs and gaining access to the latest investigative treatments, please fill out the short survey below.  All our services are provided at no cost, even free transportation services in some cases.  Appointments can typically be made within 1-3 days of contacting our center. 

Diabetes with High Triglycerides Research Study

Qualified volunteers may receive no-cost study drug with reimbursement for time & travel.

Blue Fatty Liver Instagram.jpg

If you have Type 2 Diabetes and High Triglycerides, you may already have Fatty Liver Disease. Fatty Liver Disease can lead to liver cell damage, cirrhosis or liver cancer.

You may not be experiencing symptoms and you may not be overweight.

Local physicians are looking for participants with Diabetes and High Triglycerides for a research study to assess the effects of an investigational medicine on controlling diabetes, cholesterol and liver fat.

 In general, you must:

  • Be 18-70 years of age
  • Have Type 2 Diabetes
  • Have High Triglycerides

Other criteria may apply

To proceed, we need to know whether you have fatty liver, via a 5 minute ultrasound test at our clinic. Other tests will also be performed at this visit.

If qualified and you choose to enroll, you will receive:

  • Investigational medication
  • Study-related care from our board-certified physicians
  • Compensation for your time and travel

Call our center directly at (773) 275-3500 to speak with one of our staff today

Great Lakes Clinical Trials Initiates A Healthy Digestion Study

Getting Things Moving - Kiwi Power!


Great Lakes Clinical Trials is recruiting participants for a clinical research study investigating the effects of Actazin & Livaux on aiding digestion and promoting improved bowel regularity. Actazin & Livaux are sourced from 100% Non-GMO New Zealand whole kiwifruit and carefully prepared to ensure bioactives and key nutrients are protected.

Eligible participants receive either placebo or study product which contains a collection of prebiotic compounds. Prebiotics promote a diverse microbiome by helping to feed the healthy bacteria within our gut leading to improved bloating, energy and daily bowel maintenance.

This study is looking for participants who have 3 or fewer COMPLETE and SPONTANEOUS bowel movements per week.

  • Complete means providing the feeling of complete evacuation.
  • Spontaneous means without medication or manual maneuvers.

In addition, we are seeking generally healthy participants who are:

  • Between the ages 18 to 60
  • Seeking to Advance Digestive Health through Research
  • Available for an approximately 2-month long study with 3 visits to our center

Participants will receive compensation of up to $250.


If you are interested in joining this trial, please take our screening survey by clicking the "Online Survey" button below and then one of our staff will be in touch with you shortly to determine your eligibility.

Otherwise, you can call our center directly at (773) 275-3500 to speak with one of our staff today

Come Visit Great Lakes Clinical Trials at the Mane Event and Taste of Arlington Heights

Great Lakes Clinical Trials is proud to be joining the summer fun at the Mane Event in downtown Arlington Heights on Friday, August 3 to kickoff the Million Week, in recognition of the Arlington Million race held at Arlington Park Racecourse on August 11. The Arlington Heights Chamber of Commerce partners with the Village of Arlington Heights each year to support this summer block party which attracts about 20,000 people each year.

"As an owner of a new business in Arlington Heights and as someone who grew up in the community, I couldn't be more excited to participate in this event," commented Steve Satek, President of Great Lakes Clinical Trials. "We'll have an opportunity to interact with our neighbors and help them understand the ground-breaking research opportunities our organization offers to the northwest suburban communities."

The fest is held on Vail Avenue and Campbell Street in the downtown Arlington Heights. The Mane Event -- named for a horse's mane -- is held from 5 to 11 p.m.  on Friday, August 3. It features a Business Expo until 8 p.m. as well as children's entertainment from 5 - 8 p.m.  The Mane Event is followed on Saturday, August 4th by an all-day Taste of Arlington Heights from noon - 11 p.m.  

It's a great celebration of Arlington Heights' neighbors and people from around the area who come out to enjoy the atmosphere the downtown, partake in festival activities and sit back and relax to the free musical entertainment. Over 20 restaurants, including some downtown restaurants, will be serving food both days.

Musical entertainment for the Mane Event starts with WaxWorks at 6 p.m. followed by a local favorite, Mike & Joe at 8:30 p.m.

Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer’s Disease At 18-Months

Great Lakes Clinical Trials is pleased to share this press release in regards to a Alzheimer's disease research program in which we are participating.  If you are interested in learning how to participate, please click HERE for more information.

June 5, 2018
Eisai Co., Ltd. (
Biogen Inc. (

Results Of The Phase II Study Demonstrated A Statistically Significant Difference In Amyloid Beta In Brain

 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (Aβ) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. This study, a Phase II study of 70 patients, is the first study of a BACE inhibitor to show a statistically significant difference in amyloid beta in the brain while also suggesting a delay of clinical symptom decline in exploratory endpoints. 

To download a full version of the press release, click HERE.
You can also view it directly on Biogen's website by clicking HERE or on Eisai's website by clicking HERE